

---

## Product Data Sheet

---

Product Name: Maxacalcitol-D6

Cat. No.: GC36551

### Chemical Properties

Cas. No.

SMILES O[C@@H](C[C@H](O)C/C=C)CC1=C\C=C2[C@@](CC[C@@H]3[C@@H](OCCC(C([2H]))([2H])[2H])(C([2H])([2H])[2H])O)C([H])[C@]3(C)CCC\2Formula  $C_{26}H_{36}D_6O_4$  M.Wt 424.65

Solubility DMSO : 100 mg/mL (235.49 mM; Need ultrasonic) Storage Store at -20°C, unstable in solution, ready to use.

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure 

### Background

Maxacalcitol-D6 is the deuterated form of Maxacalcitol (22-Oxacalcitriol), which is a non-calcemic vitamin D3 analog and VDR ligand of VDR-like receptors. IC50 value: Target: Maxacalcitol (22-Oxacalcitriol) suppresses parathyroid hormone (PTH) mRNA expression in vitro and in vivo. Maxacalcitol exhibits similar effects to calcitriol in osteoblast-like cells. Maxacalcitol (22-Oxacalcitriol) inhibits tumor growth of osteosarcoma in vitro in combination with all-trans retinoic acid.

[1]. Monier-Faugere et al 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. *Kidney Int.* (1999)55 821.  
 [2]. Barroga et al Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. *Res.Vet.Sci.* (2000)68 79. [3]. Inoue K, Matsui I, Hamano T, Fujii N, Shimomura A, Nakano C, Kusunoki Y, Takabatake Y, Hirata M, Nishiyama A, Tsubakihara Y, Isaka Y, Rakugi H. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pS [4]. Karashima T, Hashikawa K, Ono F, Eguchi H,

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

---

## Product Data Sheet

---

Hamada T, Ishii N, Dainichi T, Yasumoto S, Tsuruta D, Hashimoto T. Successful Treatment of Bowen's Disease with Topical Maxacalcitol. Acta Derm Venereol. 2012 Jan 26.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**